Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
Table 1
Baseline characteristics of included rheumatoid arthritis patients.
Adalimumab ( = 106)
Etanercept ( = 202)
Golimumab ( = 43)
Infliximab ( = 78)
Tocilizumab ( = 95)
valu
TNFi ( = 429)
value¥
Age (years)
52 ± 11.0
53.1 ± 13.3
55.2 ± 11.4
54.9 ± 11.9
53.8 ± 10.9
0.558
53.5 ± 12.3
0.791
Female
98 (92.5)
172 (85.2)
38 (88.4)
67 (85.9)
82 (86.3)
0.459
375 (87.4)
0.772
Caucasian ( = 456)
85 (92.4)
166 (95.4)
27 (96.4)
67 (89.3)
80 (92.0)
0.424
345 (93.5)
0.607
Disease duration (years, = 489)
12.3 ± 10.0
11.1 ± 9.0
10.2 ± 8.5
13.1 ± 10.6
10.7 ± 9.0
0.339
11.7 ± 9.5
0.372
Education (years, = 387)
7.2 ± 4.7
7.4 ± 4.7
7.5 ± 3.6
6.2 ± 4.1
7.4 ± 4.6
0.464
7.1 ± 4.5
0.611
Current smokers ( = 450)
11 (11.6)
23 (13.0)
2 (8.0)
7 (10.1)
12 (14.3)
0.884
43 (11.8)
0.522
CV comorbidity ( = 467)
50 (52.1)
68 (39.5)
14 (36.8)
28 (38.9)
40 (44.9)
0.258
160 (42.3)
0.654
Seropositive ( = 463)
80 (87.0)
142 (80.2)
29 (76.3)
61 (92.4)
73 (81.1)
0.107
312 (83.7)
0.564
Erosive ( = 380)
18 (25.4)
37 (23.7)
7 (25.9)
13 (23.6)
16 (22.5)
0.994
75 (24.3)
0.757
Previous biologics
0.24 ± 0.61
0.16 ± 0.38
0.09 ± 0.29
0.14 ± 0.39
0.81 ± 1.13
<0.001
0.17 ± 0.44
<0.001
Biologic-naïve
88 (83.0)
170 (84.2)
39 (90.7)
68 (87.2)
52 (54.7)
<0.001
365 (85.1)
<0.001
MTX
86 (81.1)
164 (81.2)
36 (83.7)
67 (85.9)
75 (79.0)
0.813
353 (82.3)
0.447
MTX dose (mg/week)
19.6 ± 4.4
18.9 ± 4.5
19.4 ± 5.2
19.6 ± 3.8
18.2 ± 4.2
0.279
19.3 ± 4.4
0.069
Corticosteroids
81 (76.4)
153 (75.7)
35 (81.4)
65 (83.3)
77 (81.1)
0.586
334 (77.9)
0.493
Corticosteroids dose (mg/day)
7.4 ± 3.3
7.3 ± 2.9
7.2 ± 2.8
7.1 ± 2.7
6.7 ± 2.4
0.530
7.3 ± 3.0
0.097
TJC28
11.1 ± 8.2
10.1 ± 7.3
9.2 ± 6.8
11.3 ± 8.2
12.4 ± 7.5
0.092
10.5 ± 7.6
0.028
SJC28
7.0 ± 5.5
6.5 ± 4.7
6.9 ± 4.6
7.2 ± 5.7
10.4 ± 6.4
<0.001
6.8 ± 5.1
<0.001
ESR (mm/h, = 522)
36.2 ± 22.9
36.9 ± 27.2
38.9 ± 27.1
37.7 ± 24.4
45.6 ± 27.1
0.073
37.1 ± 25.6
0.004
CRP (mg/dL, = 491)
2.2 ± 2.6
2.0 ± 3.1
2.2 ± 2.7
1.9 ± 1.9
2.8 ± 3.2
0.266
2.1 ± 2.7
0.035
PGH (mm, = 496)
58.7 ± 24.5
56.4 ± 22.9
59.5 ± 20.2
60.5 ± 23.6
59.8 ± 24.3
0.648
58.0 ± 23.2
0.496
PhGA (mm, = 376)
47.3 ± 20.1
51.5 ± 20.0
51.0 ± 19.1
54.4 ± 19.2
60.0 ± 17.9
0.002
51.0 ± 19.8
0.001
DAS28
5.5 ± 1.4
5.4 ± 1.3
5.4 ± 1.2
5.6 ± 1.4
6.1 ± 1.1
0.001
5.4 ± 1.3
<0.001
CDAI ( = 376)
27.7 ± 14.8
28.0 ± 12.8
26.0 ± 11.5
29.8 ± 14.9
33.3 ± 13.2
0.037
28.1 ± 13.6
0.003
SDAI ( = 361)
29.9 ± 15.4
30.6 ± 13.8
27.6 ± 12.0
31.7 ± 15.7
35.6 ± 13.1
0.056
30.4 ± 14.4
0.006
HAQ ( = 415)
1.6 ± 0.7
1.4 ± 0.6
1.5 ± 0.7
1.5 ± 0.6
1.6 ± 0.6
0.158
1.5 ± 0.6
0.150
High disease activity
DAS28 (>5.1)
68 (64.2)
120 (59.4)
28 (65.1)
51 (65.4)
74 (77.9)
0.044
267 (62.2)
0.004
CDAI (>22, = 376)
46 (60.5)
93 (65.0)
14 (51.9)
38 (64.4)
56 (78.9)
0.068
191 (62.6)
0.009
SDAI (>26, = 361)
39 (54.2)
78 (58.7)
13 (48.2)
33 (55.9)
53 (75.7)
0.036
163 (56.0)
0.003
Continuous variables presented as mean ± standard deviation; categorical variables are expressed as number (percentage). Final number of patients is indicated where data was missing. value significant at <0.05; significant differences highlighted in bold. Comparison of groups according to biologic using ANOVA or chi-square test, as appropriate; comparison of TNFi versus tocilizumab groups using Student’s -test or chi-square test, as appropriate. CDAI: clinical disease activity index; CRP: C-reactive protein; CV: cardiovascular; DAS28: disease activity score-28 joints; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; MTX: methotrexate; PGH: patient global health; PhGA: physician global assessment; SDAI: simplified disease activity index; SJC28: swollen joint count-28 joints; TJC28: tender joint count-28 joints; TNFi: tumour necrosis factor inhibitors.
